Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Odense University Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Georgetown University, MedStar Georgetown University Hospital, Hammersmith Hospital, Hospital Clínic de Barcelona, Barts Health NHS Trust, Royal London Hospital, Oncology Institute of Hope and Innovation, Hospital de Cruces, Sanofi (United States), Harvard University, Massachusetts General Hospital
Language: English
Topic: Blood groups and transfusion
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417022309